An internist and infectious diseases doctor by background, Doug has been a global corporate and operating executive at Lilly, Monsanto, Schering Plough and Mallinckrodt, a serial entrepreneur, and a venture capitalist. He led five biotech companies as CEO, including Progenitor (NASDAQ:PGEN), NeoRx (NASDAQ:NERX), Via Pharmaceuticals (NASDAQ:VIAP), Vivaldi Biosciences Inc. and Mercator Genetics Inc. Doug is Managing Partner at Health2047 Capital Partners. Doug served as Health2047 Inc.’s Chief Executive from its founding in August of 2015 until January 2018. Previously, he spent more than a decade in venture capital as an Investment Partner and General Partner at life sciences investor Bay City Capital LLC through five sequential life sciences general funds and two sector-specific funds; he was associated with the partnership from 1999-2015.
An experienced board member, Doug currently serves as a Director at Health2047 Inc. and board Chair at both Akiri Inc. and Arrowhead Pharmaceuticals Inc. He recently served as board Chair and CEO at Vivaldi Biosciences Inc. He serves on advisory boards at the University of Chicago Medicine, Johns Hopkins Bloomberg School of Public Health, Stanford Medicine, Harvard School of Public Health, and The Houston Methodist Research Institute.
Doug received MD and PhD (Virology) degrees from the University of Chicago, an MBA from the Wharton School at the University of Pennsylvania, was a Clinical and Research Fellow at Massachusetts General Hospital and Harvard Medical School, and an Attending Physician and professor at Indiana University School of Medicine.